OpGen (NASDAQ:OPGN) Now Covered by StockNews.com

StockNews.com began coverage on shares of OpGen (NASDAQ:OPGN) in a report issued on Monday morning. The firm issued a sell rating on the medical research company’s stock.

OpGen Price Performance

Shares of NASDAQ OPGN opened at $1.79 on Monday. OpGen has a 52-week low of $1.61 and a 52-week high of $38.40. The business has a fifty day moving average of $2.20 and a two-hundred day moving average of $3.52.

OpGen (NASDAQ:OPGN) last announced its quarterly earnings results on Monday, August 19th. The medical research company reported ($1.18) earnings per share (EPS) for the quarter. The firm had revenue of $0.03 million for the quarter. OpGen had a negative net margin of 1,140.36% and a negative return on equity of 1,827.76%.

Institutional Investors Weigh In On OpGen

A hedge fund recently bought a new stake in OpGen stock. Chase Investment Counsel Corp acquired a new position in OpGen, Inc. (NASDAQ:OPGN) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 331,890 shares of the medical research company’s stock, valued at approximately $230,000. Chase Investment Counsel Corp owned approximately 2.63% of OpGen as of its most recent filing with the Securities and Exchange Commission (SEC). 2.68% of the stock is owned by hedge funds and other institutional investors.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.